With nearly 70% of Phase I studies currently being outsourced*, biopharmaceutical companies need to find a partner with the scientific and therapeutic expertise, global reach, cutting-edge technologies and the breadth of services to give their studies the best chance of success.

For the past 30+ years, PAREXEL has been helping biopharmaceutical companies get their new and innovative drug treatments into the hands of those who need them most by simplifying the journey to market.

At PAREXEL, we have found that through the intelligent use of medical imaging, biopharmaceutical companies can achieve significant savings in both research timelines and resources. We enable the use of medical imaging endpoints allowing sponsors to “see” the effects of a new drug at a much earlier stage of research compared to traditional endpoints such as clinical benefit or survival times.

*Source: ISR Reports 2014-2018 Phase I Study Trends and Market Outlook

MEDICAL IMAGING HELPS THE “GO/NO-GO” DECISION

The use of novel imaging approaches in Phases I through IIa provides support for important “go/no-go” decision-making.

PAREXEL has a network of world-class Early Phase Clinical Units (in Baltimore, MD, Los Angeles, CA, Berlin, London and Bloemfontein, South Africa) concentrating on the use of novel imaging approaches for clinical studies. We have direct access to:

- Research-qualified 3T MRI scanners:
  - Capable of supporting imaging protocols using structural (sMRI), functional (fMRI), diffusion tensor imaging (DTI) and arterial spin labeling (ASL)
  - That have undergone cross-validated research protocols to ensure harmonized image quality and data acquisition between sites
- Computerized tomography (CT) scanners, structural magnetic resonance imaging (sMRI), functional MRI (fMRI), arterial spin labeling (ASL) perfusion MRI, ultrasound, double photon absorptiometry with dual-energy X-ray source (DEXA) scans, and X-rays
- A positron emission tomography (PET) imaging facility, including use of investigational radioligands supporting your Phase I PET study needs, through our collaboration with the Johns Hopkins University School of Medicine
- A team of dedicated medical imaging and clinical scientist experts

WE HAVE CONDUCTED

114 EARLY PHASE STUDIES
49 in CNS alone

using medical imaging over the last 5 years
Our Early Phase imaging capabilities are complemented by validated Quantitative EEG (QEEG), Evoked Response Potential (ERP) protocols, and customized behavioral assessments resulting in neural-circuitry analyses that translate pre-clinical approaches into early development programs, building on the NIH’s Research Domain Criteria (RDoC) approach for CNS disorders.

At PAREXEL we look at each study individually to see how we can use medical imaging to gather more study data so that clients can make the important decisions they need to as soon as possible.

CONTINUING YOUR JOURNEY TO APPROVAL

At PAREXEL, the use of medical imaging solutions won’t end after Phase I. Medical Imaging Solutions from PAREXEL® Informatics combines our in-house medical staff, external scientific advisors and key opinion leaders, to design and deploy the right solutions tailored to meet your individual study requirements at any phase of research.

We have managed over 900 imaging studies involving over 54,000 sites and 300,000 subjects across all the major therapeutic areas including:

- Oncology
- Neurology
- Musculoskeletal
- Cardiovascular
- Advanced Imaging (COPD, HIV, Obesity, etc.)

We are always available for a conversation.

Yves Grenon
Vice President and Worldwide Head, Business Development, Early Phase
T +1 781 434 4053
yves.grenon@PAREXEL.com
WHEREVER YOUR JOURNEY TAKES YOU, WE’RE CLOSE BY.

CORPORATE HEADQUARTERS
195 West Street
Waltham, MA 02451
USA
+1 781 487 9900

Offices across Europe, Asia and the Americas

www.PAREXEL.com